Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ENDRA Life Sciences Inc. (NDRA) SEC filings page provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q, 8‑K, registration statements and proxy materials. These documents explain how ENDRA is developing its Thermo Acoustic Enhanced UltraSound (TAEUS®) platform for liver fat measurement and other thermoacoustic applications, and how it manages capital and risk as a Nasdaq‑listed issuer in the electromedical and electrotherapeutic apparatus manufacturing industry.
Through annual and quarterly reports, investors can review detailed discussions of ENDRA’s business strategy, risk factors, research and development priorities, and its focus on steatotic liver disease (SLD), metabolic dysfunction‑associated steatohepatitis (MASH) and GLP‑1 therapy management. Current reports on Form 8‑K describe material events such as private placements with warrants, at‑the‑market (ATM) equity agreements, the launch of a digital asset treasury (DAT) strategy, and the engagement of Arca Investment Management and Anchorage Digital Bank to manage and custody cryptocurrency holdings.
Filings also document corporate governance and capital structure decisions, including amendments to the certificate of incorporation to increase authorized common shares, updates to the 2016 Omnibus Incentive Plan, and Nasdaq listing compliance matters related to stockholders’ equity. Registration statements on Form S‑1/A outline proposed offerings, use of proceeds for TAEUS development and DAT activities, and extensive risk factor sections addressing both medical device and digital asset considerations.
On Stock Titan, these filings are paired with AI‑powered summaries that highlight key points from lengthy documents, helping users quickly understand complex topics such as De Novo regulatory plans for TAEUS Liver, equity financing terms, warrant structures and DAT‑related risk disclosures. Investors can also monitor insider‑related information through ownership tables and compensation discussions included in proxy statements and periodic reports.
On June 11, 2025, ENDRA Life Sciences Inc. (NDRA) filed a Form 4 showing that director Lou Basenese was granted 5,384 restricted stock units (RSUs), convertible to common stock on a one-for-one basis. The award, recorded at a transaction price of $0, reflects routine equity compensation rather than an open-market purchase. All RSUs vest in full on June 11, 2026. After the grant, Basenese beneficially owns 5,385 NDRA common shares, held directly. No derivative securities, sales, or dispositions were reported. Given the modest share count relative to ENDRA’s total float, the filing is viewed as neutral in financial materiality, but it marginally improves insider-shareholder alignment.
On June 11, 2025, ENDRA Life Sciences (NDRA) director Michael Harsh received 5,384 restricted stock units (RSUs), as disclosed in a Form 4 filed on July 1, 2025. The RSUs carry an exercise price of $0 and convert to common stock on a one-for-one basis.
Vesting schedule: the entire award vests on June 11, 2026. After the grant, Harsh beneficially owns 5,386 NDRA common shares, held directly. No derivative instruments or share disposals were reported, and no cash changed hands.
This appears to be a routine equity-compensation grant designed to encourage long-term alignment between the director and shareholders. The transaction is too small to impact NDRA’s share count, earnings or liquidity, but it does marginally increase insider ownership.
ENDRA Life Sciences Inc. (NDRA) filed a Form 4 on 1 July 2025 for director Anthony DiGiandomenico. On 11 June 2025 the director was granted 5,384 restricted stock units (RSUs) that convert to common shares on a 1-for-1 basis and vest in full on 11 June 2026. No cash was exchanged (reported price = $0), indicating a routine equity-compensation award rather than an open-market purchase. After the grant, DiGiandomenico’s direct beneficial ownership increased to 5,443 common shares, implying a prior holding of about 59 shares. No derivative transactions or dispositions were disclosed. The filing modestly tightens insider-shareholder alignment but, given the small number of shares relative to ENDRA’s total float, the market impact is expected to be limited.